Cargando…

Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects

PURPOSE: Rolapitant is a neurokinin-1 receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed chemotherapy-induced nausea and vomiting. We evaluated the effects of rolapitant oral on the pharmacokinetics of probe substrates for cytochrome P45...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jing, Zhang, Zhi-Yi, Lu, Sharon, Powers, Dan, Kansra, Vikram, Wang, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373243/ https://www.ncbi.nlm.nih.gov/pubmed/30084103 http://dx.doi.org/10.1007/s00520-018-4331-x

Ejemplares similares

Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
por: Barbour, S., et al.
Publicado: (2017)

The Effects of H(2)S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
por: Wang, Xianqin, et al.
Publicado: (2013)

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype-dependent
por: Michaud, Veronique, et al.
Publicado: (2013)

The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity
por: Bojić, Mirza, et al.
Publicado: (2019)

In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5
por: Lim, Sharoen Yu Ming, et al.
Publicado: (2022)

The Evaluation of CYP2D6, CYP2C9, CYP2C19, and CYP2B6 Phenoconversion in Post-Mortem Casework: The Challenge of Forensic Toxicogenetics
por: Giorgetti, Arianna, et al.
Publicado: (2023)

CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole
por: Denisenko, Natalia P, et al.
Publicado: (2018)

Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Carvalho Henriques, Beatriz, et al.
Publicado: (2021)

CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
por: Metzger, Ingrid F., et al.
Publicado: (2019)

Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population
por: Ota, Tomoko, et al.
Publicado: (2015)

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
por: Kudzi, William, et al.
Publicado: (2009)

Correction: Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Henriques, Beatriz Carvalho, et al.
Publicado: (2022)

Evaluation of CYP2C9 Activity in Rats: Use of Tolbutamide Alone and in Combined with Bupropion
por: Qiu, Xiangjun, et al.
Publicado: (2014)

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19
por: Swen, J. J., et al.
Publicado: (2011)

Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV-infected patients
por: Zhang, Y, et al.
Publicado: (2010)

Global variation in CYP2C8–CYP2C9 functional haplotypes
por: Speed, William C, et al.
Publicado: (2009)

Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity
por: Rodríguez-Morató, Jose, et al.
Publicado: (2019)

CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes
por: Schmidt, R, et al.
Publicado: (2004)

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19
por: Koopmans, Anne B., et al.
Publicado: (2021)

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
por: Kee, Ping Siu, et al.
Publicado: (2023)

Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP
por: Tan, Ming‐Liang, et al.
Publicado: (2017)

Crystal Structure of CYP2B6 in Complex with an Efavirenz Analog
por: Shah, Manish B., et al.
Publicado: (2018)

Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype
por: Dujic, Tanja, et al.
Publicado: (2021)

Association of CYP2C19, CYP2D6 and CYP3A4 Genetic Variants on Primaquine Hemolysis in G6PD-Deficient Patients
por: Macêdo, Marielle M., et al.
Publicado: (2023)

Functional characterization of the defective CYP2C9 variant CYP2C9*18
por: Liu, Jian, et al.
Publicado: (2021)

Common CYP2D6, CYP2C9, and CYP2C19 Gene Variants, Health Anxiety, and Neuroticism Are Not Associated With Self-Reported Antidepressant Side Effects
por: Maggo, Simran, et al.
Publicado: (2019)

Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe
por: Petrović, Jelena, et al.
Publicado: (2019)

CYP2D6 and CYP2C19 Genes Associated with Tricontinental and Latin American Ancestry of Peruvians
por: Alvarado, Angel T., et al.
Publicado: (2023)

A Robust and Fast/Multiplex Pharmacogenetics Assay to Simultaneously Analyze 17 Clinically Relevant Genetic Polymorphisms in CYP3A4, CYP3A5, CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, and VKORC1 Genes
por: Tron, Camille, et al.
Publicado: (2022)

A Systematically Combined Genotype and Functional Combination Analysis of CYP2E1, CYP2D6, CYP2C9, CYP2C19 in Different Geographic Areas of Mainland China – A Basis for Personalized Therapy
por: Wu, Zhenqiang, et al.
Publicado: (2013)

Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations
por: Sychev, Dmitrij Alekseevitch, et al.
Publicado: (2017)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2022)

Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2016)

CYP2C8 and CYP2C9 mRNA expression profile in the human fetus
por: Johansson, Maria, et al.
Publicado: (2014)

Evaluation of Drug–Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor
por: Xiao, Jim J., et al.
Publicado: (2018)

Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma
por: Khedhaier, Achraf, et al.
Publicado: (2008)

CYP2C19 and CYP2D6 Genotypes and Metabolizer Status Distribution in a Bulgarian Psychiatric Cohort
por: Ivanov, Hristo Y., et al.
Publicado: (2022)

Expression of CYP2A6, CYP2D6 and CYP4A11 Polymorphisms in COS7 Mammalian Cell Line
por: Lee, Hye Ja, et al.
Publicado: (2011)

Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans
por: Elbe, Annika, et al.
Publicado: (2022)

Inhibitory Potency of 8-Methoxypsoralen on Cytochrome P450 2A6 (CYP2A6) Allelic Variants CYP2A6*15, CYP2A6*16, CYP2A6*21 and CYP2A6*22: Differential Susceptibility Due to Different Sequence Locations of the Mutations
por: Tiong, Kai Hung, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_641vfvk7ri4gjdrf4k3at0h7gv